A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Botswana, Eswatini, Malawi, and Uganda4 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 580 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 10 Jul 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Doxycycline hyclate
- Standard of Care for STI prevention
- Record updated
- 20 October 2026
Who can take part
- Age
- 13 years to 34 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- All adolescent and adult young women who meet all the following criteria are eligible for inclusion in this study:
- Age 13-34 years, inclusive
- In good health as determined by past medical history, medication use, and targeted physical examination,; If not living with HIV, negative HIV test conducted at screening; If living with HIV, on an antiretroviral regimen for ≥3 months
- Report at least two of the following:; Treatment for a curable STI (not including HIV) in the past 12 months prior to screening; Self-report of condomless (oral, vaginal, and/or anal) intercourse at least once in the 30 days prior to screening; Has had two or more partners in the past 6 months
- ≥ 45 kilograms (99 pounds) in weight
- Anticipate living in the study area for 12 months and no plans for travel away from the study site for a time period that would interfere with product resupply and study participation
- Willing to undergo all required study procedures that may include Directly/Video observed therapy (D/VOT); and
- Provide written informed consent to participate in the study; If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with Institutional Review Board (IRB)/Ethics Committee (EC) policies: Willing and able to provide written informed consent for study participation; If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB/EC policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation
Who cannot take part
- Current (within 30 days of Enrollment) or anticipated use of a medication with a contraindicated interaction to doxycycline (e.g., iron, barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin)
- Current or planned use of doxycycline for a prolonged period (> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis
- Prolonged antibiotic use (> 2 weeks) within the last 30 days prior to enrollment
- Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, unless approved by the Protocol Team in writing
- Positive NAAT for CT or NG or with evidence of untreated syphilis infection
- Documented history of tetracycline allergy or self-reports an allergy to tetracyclines
- Any other medical condition, medical/behavioral intervention, or other conditions that, in the opinion of the clinical site Principal Investigator/Investigator of Record (PI/IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results
- All adolescent and adult young women who meet any of the following criteria will be excluded from this study:
- Is male
- Pregnant, or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 13 and 34 years old?
Where is this trial?
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is for people who may get sexually transmitted infections (STIs). Approximately 580 African adolescent and young adult women ages 13-34 in Africa will be included in this study. Study participation is approximately 52 weeks (1 year). Participants will be randomized in a 1:1 ratio to receive doxycycline prophylaxis or standard of care.
The 2 groups in the trial
- Doxycycline hyclate 200 mgTreatment being tested
Participants randomized to the intervention arm will receive doxycycline hyclate 200 mg (2 x 100mg) administered orally once weekly, for the duration of 51 weeks.
Treatment: Doxycycline hyclate
- Standard of CareExisting treatment, for comparison
Participants randomized to the standard-of-care arm alone will not receive doxycycline prophylaxis and will receive local standard of care for STI prevention per local guidelines.
Treatment: Standard of Care for STI prevention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Weekly Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Young African Women
- Criteria questions
- Built from NCT07884240, who can take part
- Record updated
- 20 October 2026